---
title: "Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291569499.md"
description: "Unicycive Therapeutics reported a preliminary unaudited cash balance of $61.4 million as of June 30, 2026. The company noted these figures are management-prepared and subject to adjustment upon audit. While analyst ratings suggest a 'Buy' with a $15 target, TipRanks' AI Analyst rates UNCY as 'Neutral' due to weak financials, including no revenue and ongoing cash burn, alongside bearish technical indicators."
datetime: "2026-07-02T14:58:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291569499.md)
  - [en](https://longbridge.com/en/news/291569499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291569499.md)
generator: "portal-rs"
---

# Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position

Unicycive Therapeutics ( (UNCY) ) has shared an announcement.

As of June 30, 2026, Unicycive Therapeutics reported an unaudited ending cash balance of approximately $61.4 million, reflecting its liquidity position at the close of the second quarter of 2026. The company emphasized that these preliminary financial results were prepared by management and have not yet been audited, reviewed, or subject to any assurance procedures by its independent registered public accounting firm or other external accountants, which may be relevant for investors assessing the reliability of the figures.

This lack of external validation indicates that the reported cash balance and related preliminary data could be subject to adjustment once formal review processes are completed. Stakeholders, including shareholders and creditors, may therefore interpret these figures as an early indication of financial health rather than definitive results, underscoring the importance of awaiting finalized second-quarter financial statements before drawing firm conclusions about the company’s operational and funding outlook.

The most recent analyst rating on (UNCY) stock is a Buy  
 with a $15.00 price target.  
 To see the full list of analyst forecasts on Unicycive Therapeutics stock,  
 see the UNCY Stock Forecast page. 

**Spark’s Take on UNCY Stock**

According to Spark, TipRanks’ AI Analyst, UNCY is a Neutral.

The score is primarily held down by weak financial performance (no revenue base, sizable losses, and ongoing cash burn) and bearish technicals (price below major moving averages with negative MACD). Valuation provides limited offset because the company is loss-making (negative P/E) and offers no dividend yield.

To see Spark’s full report on UNCY stock,  
 click here. 

**More about Unicycive Therapeutics**

Unicycive Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapies for serious medical conditions. The company targets markets where existing treatment options are limited or inadequate, aiming to improve patient outcomes through innovative drug candidates and clinical programs.

**Average Trading Volume:** 1,314,566

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $141M

Find detailed analytics on UNCY stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [A mysterious free AI model is impressing developers. And nobody knows who made it.](https://longbridge.com/en/news/296687985.md)
- [Why Wolfe Research Just Named Nvidia Stock Its Top AI Pick](https://longbridge.com/en/news/296822517.md)
- [AI Stocks For Businesses Chasing Lower Costs and Higher Productivity](https://longbridge.com/en/news/296687382.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**